| scholarly article | Q13442814 |
| P2093 | author name string | Tony Hunter | |
| Zhiyong Wang | |||
| O Jameel Shah | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | insulin resistance | Q1053470 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 1650-1656 | |
| P577 | publication date | 2004-09-01 | |
| P1433 | published in | Current Biology | Q1144851 |
| P1476 | title | Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies | |
| P478 | volume | 14 |
| Q36876556 | 14-3-3 proteins regulate Tctp-Rheb interaction for organ growth in Drosophila. |
| Q55691977 | A TFEB nuclear export signal integrates amino acid supply and glucose availability. |
| Q24655791 | A complex interplay between Akt, TSC2 and the two mTOR complexes |
| Q30396975 | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas |
| Q37223263 | A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles |
| Q40380384 | A novel regulation of IRS1 (insulin receptor substrate-1) expression following short term insulin administration. |
| Q22241925 | AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling |
| Q34447043 | AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. |
| Q37948152 | AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets |
| Q92666563 | AMPK directly activates mTORC2 to promote cell survival during acute energetic stress |
| Q39652396 | AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia |
| Q39741365 | AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability |
| Q36802449 | ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo |
| Q34595624 | AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and Insulin/Insulin-Like Growth Factor 1 |
| Q24651443 | Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2 |
| Q39328713 | Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis |
| Q34200875 | Activation of PI3K/AKT and MAPK Pathway through a PDGFRβ-Dependent Feedback Loop Is Involved in Rapamycin Resistance in Hepatocellular Carcinoma |
| Q29615179 | Activation of a metabolic gene regulatory network downstream of mTOR complex 1 |
| Q36749704 | Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin resistance in rats |
| Q50347315 | Activation of the Stress Response Kinase JNK (c-Jun N-terminal Kinase) Attenuates Insulin Action in Retina through a p70S6K1-dependent Mechanism |
| Q35236076 | Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. |
| Q38681576 | Advances in systemic therapy for metastatic breast cancer: future perspectives. |
| Q38893460 | Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration |
| Q36614145 | Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions |
| Q35684972 | Akt and PTEN: beta-cell mass and pancreas plasticity. |
| Q40164038 | Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition |
| Q39266844 | Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors |
| Q35034550 | Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer |
| Q37162256 | Amino acid-sensing mTOR signaling is involved in modulation of lipolysis by chronic insulin treatment in adipocytes |
| Q34063643 | Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. |
| Q24629305 | An emerging role for TOR signaling in mammalian tissue and stem cell physiology |
| Q36210035 | Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex |
| Q37397413 | Anticarcinogenic effect of quercetin by inhibition of insulin-like growth factor (IGF)-1 signaling in mouse skin cancer |
| Q39604786 | Antidiabetic Effect of Oleanolic Acid: A Promising Use of a Traditional Pharmacological Agent |
| Q40014624 | Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts. |
| Q37736908 | Are we on the brink of nonsurgical treatment for ameloblastoma? |
| Q41880723 | Arrest of myelination and reduced axon growth when Schwann cells lack mTOR. |
| Q37677015 | Autophagy in Diabetic Retinopathy |
| Q35276016 | Autophagy in tumor suppression and cancer therapy |
| Q24676203 | Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis |
| Q42516714 | Basal activation of p70S6K results in adipose-specific insulin resistance in protein-tyrosine phosphatase 1B -/- mice. |
| Q37262812 | Beta-cell failure as a complication of diabetes |
| Q47703395 | Biochemical and cellular properties of insulin receptor signalling |
| Q41776053 | Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice |
| Q64070786 | Boolean network modeling of β-cell apoptosis and insulin resistance in type 2 diabetes mellitus |
| Q33605329 | Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. |
| Q24295164 | Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function |
| Q36533391 | Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation. |
| Q48101340 | Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents |
| Q35947377 | Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging |
| Q39668305 | Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). |
| Q24645183 | Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1 |
| Q34102206 | Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes |
| Q30665241 | Class III PI3K regulates organismal glucose homeostasis by providing negative feedback on hepatic insulin signalling. |
| Q37871915 | Clinical activity of mammalian target of rapamycin inhibitors in solid tumors |
| Q42700646 | Clk2 and B56β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. |
| Q34977124 | Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma |
| Q34287101 | Combinatorial drug therapy for cancer in the post-genomic era. |
| Q84565122 | Comment on “A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation”: Building a Model of the mTOR Signaling Network with a Potentially Faulty Tool |
| Q37643431 | Common corruption of the mTOR signaling network in human tumors |
| Q35882137 | Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy |
| Q37969685 | Conserved RB functions in development and tumor suppression |
| Q40811649 | Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. |
| Q36926241 | Constitutively active Rheb induces oncogenic transformation |
| Q39186250 | Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer |
| Q89013204 | Critical role for the Tsc1-mTORC1 pathway in β-cell mass in Pdx1-deficient mice |
| Q38932265 | Curcumin improves high glucose-induced INS-1 cell insulin resistance via activation of insulin signaling |
| Q27311242 | Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes |
| Q28255366 | Current development of mTOR inhibitors as anticancer agents |
| Q38832980 | DNAJB3/HSP-40 cochaperone improves insulin signaling and enhances glucose uptake in vitro through JNK repression |
| Q37355543 | Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors |
| Q35757215 | Decreased IRS signaling impairs beta-cell cycle progression and survival in transgenic mice overexpressing S6K in beta-cells |
| Q33619407 | Dennd3 functions as a guanine nucleotide exchange factor for small GTPase Rab12 in mouse embryonic fibroblasts |
| Q48240280 | Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. |
| Q36402424 | Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells |
| Q37412018 | Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells |
| Q100512363 | Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation |
| Q24550891 | Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells |
| Q35604279 | Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2 |
| Q89697546 | Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer |
| Q39381614 | Divergent Metabolic Regulation of Autophagy and mTORC1-Early Events in Alzheimer's Disease? |
| Q49959221 | Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells |
| Q27321555 | Dynamic modelling of pathways to cellular senescence reveals strategies for targeted interventions |
| Q33619056 | Dynamic switch of negative feedback regulation in Drosophila Akt-TOR signaling |
| Q53696764 | Dysglycaemia, Inflammation and Psychosis: Findings From the UK ALSPAC Birth Cohort. |
| Q38978791 | Dysregulated mTORC1-Dependent Translational Control: From Brain Disorders to Psychoactive Drugs |
| Q34380413 | Dysregulation of the TSC-mTOR pathway in human disease |
| Q37548879 | Dysregulation of the mTOR pathway in p53-deficient mice |
| Q36106341 | E4orf1 induction in adipose tissue promotes insulin-independent signaling in the adipocyte |
| Q37102096 | Eating on the fly: function and regulation of autophagy during cell growth, survival and death in Drosophila |
| Q47634582 | Effect of Chronic Alcohol Abuse on Anabolic and Catabolic Signaling Pathways in Human Skeletal Muscle |
| Q79864248 | Effect of sirolimus treatment on gene expression in renal transplant patients |
| Q45962698 | Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model. |
| Q28511429 | Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2 |
| Q36194753 | Emerging role of autophagy in kidney function, diseases and aging |
| Q38964435 | Emerging role of mTOR in the response to cancer therapeutics |
| Q42837135 | Engineering of chaperone systems and of the unfolded protein response |
| Q34755802 | Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex |
| Q88316150 | Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR |
| Q36557541 | Eukaryotic initiation factor 2B and its role in alterations in mRNA translation that occur under a number of pathophysiological and physiological conditions |
| Q38081233 | Everolimus in colorectal cancer |
| Q37457794 | Everolimus induces Met inactivation by disrupting the FKBP12/Met complex |
| Q36902840 | Expanding mTOR signaling |
| Q38667730 | Express yourself: how PP2A-B55(Pab1) helps TORC1 talk to TORC2. |
| Q37257933 | Expression and function of the insulin receptor substrate proteins in cancer |
| Q37269368 | Fas-associated protein with death domain (FADD) regulates autophagy through promoting the expression of Ras homolog enriched in brain (Rheb) in human breast adenocarcinoma cells |
| Q28509303 | Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2 |
| Q37680256 | Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer |
| Q33790320 | Formal Modeling of mTOR Associated Biological Regulatory Network Reveals Novel Therapeutic Strategy for the Treatment of Cancer |
| Q38012951 | From genes to cognition in tuberous sclerosis: Implications for mTOR inhibitor-based treatment approaches |
| Q33750454 | From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis |
| Q39014611 | Functional Proteomics Identifies Acinus L as a Direct Insulin- and Amino Acid-Dependent Mammalian Target of Rapamycin Complex 1 (mTORC1) Substrate. |
| Q39269303 | Functional inactivation of Rb sensitizes cancer cells to TSC2 inactivation induced cell death |
| Q28593244 | Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression |
| Q36393621 | Ghrelin contributes to derangements of glucose metabolism induced by rapamycin in mice |
| Q37439028 | Global IRS-1 phosphorylation analysis in insulin resistance |
| Q40396199 | Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic alpha-cells |
| Q34620724 | Growing knowledge of the mTOR signaling network |
| Q38631149 | Growth factor, energy and nutrient sensing signalling pathways in metabolic ageing. |
| Q37044197 | HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells |
| Q39452567 | Heparin-Binding EGF-Like Growth Factor (HB-EGF) Mediates 5-HT-Induced Insulin Resistance Through Activation of EGF Receptor-ERK1/2-mTOR Pathway |
| Q34060841 | Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21. |
| Q40013894 | Hepatic overexpression of a dominant negative form of raptor enhances Akt phosphorylation and restores insulin sensitivity in K/KAy mice |
| Q50624147 | Heterogeneous nuclear ribonucleoprotein E1 regulates protein disulphide isomerase translation in oxidized low-density lipoprotein-activated endothelial cells |
| Q42111573 | Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish |
| Q47273402 | High-Protein Diets Alters Body Composition and Improves Insulin Resistance in a Rat Model of Low Birth Weight |
| Q33838971 | Hormesis and Defense of Infectious Disease |
| Q35645142 | Hormesis does not make sense except in the light of TOR-driven aging |
| Q37380692 | Human cytomegalovirus protein UL38 inhibits host cell stress responses by antagonizing the tuberous sclerosis protein complex |
| Q40995740 | Hyperactive mTORC1 signaling is unaffected by metformin treatment in aged skeletal muscle |
| Q33581982 | IRS1 regulation by Wnt/beta-catenin signaling and varied contribution of IRS1 to the neoplastic phenotype |
| Q37587810 | IRS1Ser³⁰⁷ phosphorylation does not mediate mTORC1-induced insulin resistance |
| Q35945000 | Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance |
| Q24680264 | Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity |
| Q91986748 | Impact of growth factor content on proliferation of mesenchymal stromal cells derived from adipose tissue |
| Q42136011 | In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis |
| Q37561244 | Influence of miR-155 on Cell Apoptosis in Rats with Ischemic Stroke: Role of the Ras Homolog Enriched in Brain (Rheb)/mTOR Pathway. |
| Q24318126 | Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells |
| Q29618030 | Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer |
| Q40121018 | Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one |
| Q39847621 | Inhibitor hijacking of Akt activation |
| Q35440540 | Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. |
| Q50481460 | Inpp5e suppresses polycystic kidney disease via inhibition of PI3K/Akt-dependent mTORC1 signaling |
| Q33556119 | Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation |
| Q26823171 | Insulin receptor signaling in normal and insulin-resistant states |
| Q50226931 | Insulin regulation of gluconeogenesis |
| Q30417125 | Insulin resistance without elevated mammalian target of rapamycin complex 1 activity in muscles of mice fed a high-fat diet |
| Q33480974 | Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway |
| Q64245545 | Integrative Analyses of Genes Associated with Subcutaneous Insulin Resistance |
| Q58606481 | Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis |
| Q36600294 | Investigating mammalian target of rapamycin inhibitors for their anticancer properties |
| Q39724708 | Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of rapamycin/S6 kinase 2 pathway |
| Q30300188 | Involvement of mTOR in Type 2 CRF Receptor Inhibition of Insulin Signaling in Muscle Cells |
| Q42563623 | Irs1 serine 307 promotes insulin sensitivity in mice |
| Q28071388 | Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives |
| Q35992132 | K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas |
| Q28513499 | Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys |
| Q36292001 | Koschei the immortal and anti-aging drugs |
| Q37383513 | LKB1 and AMP-activated protein kinase control of mTOR signalling and growth |
| Q36023320 | LST8 regulates cell growth via target-of-rapamycin complex 2 (TORC2). |
| Q36598687 | Leptin signaling and circuits in puberty and fertility |
| Q39579138 | Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. |
| Q35554147 | Livers with constitutive mTORC1 activity resist steatosis independent of feedback suppression of Akt. |
| Q36771317 | Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism |
| Q33918399 | Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma |
| Q40002274 | Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis |
| Q47236254 | Low Molecular Weight Fucoidan Improves Endoplasmic Reticulum Stress-Reduced Insulin Sensitivity through AMP-Activated Protein Kinase Activation in L6 Myotubes and Restores Lipid Homeostasis in a Mouse Model of Type 2 Diabetes |
| Q42595723 | Lymphangioleiomyomatosis: A Monogenic Model of Malignancy |
| Q52366507 | MAP4K3 mediates amino acid-dependent regulation of autophagy via phosphorylation of TFEB. |
| Q34126334 | MAPK/ERK signaling regulates insulin sensitivity to control glucose metabolism in Drosophila |
| Q25255189 | MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development |
| Q37570804 | Mammalian target of rapamycin and diabetes: what does the current evidence tell us? |
| Q38002007 | Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications |
| Q35107703 | Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy |
| Q37243975 | Mechanisms of high-glucose/insulin-mediated desensitization of acute insulin-stimulated glucose transport and Akt activation |
| Q34077361 | Metabolic crosstalk: molecular links between glycogen and lipid metabolism in obesity |
| Q37376589 | Metabolic effects of milk protein intake strongly depend on pre-existing metabolic and exercise status |
| Q55494305 | Metformin treatment ameliorates diabetes‐associated decline in hippocampal neurogenesis and memory via phosphorylation of insulin receptor substrate 1. |
| Q33733319 | Metformin: a therapeutic opportunity in breast cancer |
| Q35573369 | Mice lacking neutral amino acid transporter B(0)AT1 (Slc6a19) have elevated levels of FGF21 and GLP-1 and improved glycaemic control |
| Q37078685 | MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells |
| Q34996173 | Milk consumption during pregnancy increases birth weight, a risk factor for the development of diseases of civilization |
| Q35612950 | Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B |
| Q38080079 | Molecular Mechanisms of Insulin Resistance in Diabetes |
| Q38593252 | Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. |
| Q33498333 | Molecular characterization of preneoplastic lesions provides insight on the development of renal tumors |
| Q35740772 | Molecular damage in cancer: an argument for mTOR-driven aging |
| Q34877773 | Molecular mechanisms of insulin resistance in type 2 diabetes mellitus |
| Q38866763 | Molecular mechanisms of mTOR regulation by stress |
| Q36330644 | Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans |
| Q36862768 | Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response |
| Q35764401 | NCI's provocative questions on cancer: some answers to ignite discussion |
| Q28082002 | Natural history of β-cell adaptation and failure in type 2 diabetes |
| Q62868028 | Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation |
| Q33775384 | Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. |
| Q48506350 | New Insights Into the Role of mTOR Signaling in the Cardiovascular System. |
| Q30537554 | Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession |
| Q38539754 | Nutrient Excess in AMPK Downregulation and Insulin Resistance. |
| Q39663338 | Nutrient withdrawal rescues growth factor-deprived cells from mTOR-dependent damage |
| Q24535576 | Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation |
| Q35080563 | Nutrigerontology: why we need a new scientific discipline to develop diets and guidelines to reduce the risk of aging-related diseases |
| Q36062176 | Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to |
| Q41760820 | Opposite effects of tor1 and tor2 on nitrogen starvation responses in fission yeast |
| Q38046539 | Overlapped metabolic and therapeutic links between Alzheimer and diabetes. |
| Q35613890 | PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR |
| Q28246822 | PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade |
| Q38712234 | PRAS40 alleviates neurotoxic prion peptide-induced apoptosis via mTOR-AKT signaling. |
| Q33306700 | PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. |
| Q24300915 | PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase |
| Q37500523 | PRAS40: target or modulator of mTORC1 signalling and insulin action? |
| Q34887795 | Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway |
| Q39032609 | Parasite excretory-secretory products and their effects on metabolic syndrome |
| Q41614453 | Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. |
| Q35370616 | Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling |
| Q41579911 | Phosphorylation of the translation initiation factor eIF2α at serine 51 determines the cell fate decisions of Akt in response to oxidative stress |
| Q39746584 | Plumbagin, isolated from Plumbago zeylanica, induces cell death through apoptosis in human pancreatic cancer cells |
| Q36958965 | Pluralistic and stochastic gene regulation: examples, models and consistent theory. |
| Q28393474 | Plzf Regulates Germline Progenitor Self-Renewal by Opposing mTORC1 |
| Q83031840 | Potent and selective thiophene urea-templated inhibitors of S6K |
| Q36809416 | Potential for therapeutic manipulation of the UPR in disease |
| Q36776922 | Predictors and prevention of diabetic cardiomyopathy. |
| Q38034440 | Profiling mTOR pathway in neuroendocrine tumors. |
| Q34127512 | Progeria syndromes and ageing: what is the connection? |
| Q37760379 | Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases |
| Q39586316 | Protein expression profiles of C3H 10T1/2 murine fibroblasts and of isogenic cells transformed by the H1047R mutant of phosphoinositide 3-kinase (PI3K). |
| Q34202692 | RAS Interaction with PI3K: More Than Just Another Effector Pathway |
| Q64092570 | Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells |
| Q42415993 | Rapamycin Augments the NMDA-Mediated TNF Suppression of MRSA-Stimulated RAW264.7 Murine Macrophages |
| Q24644623 | Rapamycin and mTOR kinase inhibitors |
| Q36977162 | Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice. |
| Q51803667 | Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism |
| Q35966086 | Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity |
| Q34078704 | Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo |
| Q37950771 | Rapamycin passes the torch: a new generation of mTOR inhibitors |
| Q36546330 | Rapamycin preserves gut homeostasis during Drosophila aging |
| Q40887263 | Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease |
| Q38997125 | Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium |
| Q90431532 | Rapamycin, proliferation and geroconversion to senescence |
| Q39832067 | Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR |
| Q27663877 | Ras Homolog Enriched in Brain (Rheb) Enhances Apoptotic Signaling |
| Q46961792 | Ras mediates cell survival by regulating tuberin |
| Q29614734 | Ras, PI(3)K and mTOR signalling controls tumour cell growth |
| Q36739499 | Recent Advances in Adipose mTOR Signaling and Function: Therapeutic Prospects |
| Q47845996 | Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides |
| Q36602630 | Regulating insulin signaling and beta-cell function through IRS proteins |
| Q29614478 | Regulation of TORC1 by Rag GTPases in nutrient response |
| Q40390881 | Regulation of adipocyte differentiation by distinct subcellular pools of protein kinase B (PKB/Akt). |
| Q33886820 | Regulation of basal cellular physiology by the homeostatic unfolded protein response |
| Q28272571 | Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2 |
| Q24531971 | Regulation of mTOR and cell growth in response to energy stress by REDD1. |
| Q99214216 | Regulation of mTORC2 Signaling |
| Q39217640 | Regulation of neurogenesis and epidermal growth factor receptor signaling by the insulin receptor/target of rapamycin pathway in Drosophila |
| Q37856383 | Regulation of the SREBP transcription factors by mTORC1. |
| Q87449061 | Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin |
| Q37079765 | Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function |
| Q35847671 | Resveratrol Attenuates Doxorubicin-Induced Cardiomyocyte Death via Inhibition of p70 S6 Kinase 1-Mediated Autophagy |
| Q26852743 | Reviewing the Effects of L-Leucine Supplementation in the Regulation of Food Intake, Energy Balance, and Glucose Homeostasis |
| Q34665970 | Rheb1 is required for mTORC1 and myelination in postnatal brain development |
| Q37726439 | Ribosomal protein S6 kinase from TOP mRNAs to cell size |
| Q35176085 | Ribosomal protein mutations induce autophagy through S6 kinase inhibition of the insulin pathway |
| Q39771171 | Rictor is a novel target of p70 S6 kinase-1. |
| Q35634446 | Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons |
| Q42491145 | Role of Ragulator in the Regulation of Mechanistic Target of Rapamycin Signaling in Podocytes and Glomerular Function |
| Q90230822 | Roles of mTOR Signaling in Tissue Regeneration |
| Q28397712 | Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema |
| Q42168201 | S6K1 deficiency protects against apoptosis in hepatocytes |
| Q28509658 | S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response |
| Q42767363 | S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. |
| Q28476186 | Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling |
| Q36296657 | Sensitization of Cervical Cancer Cells to Cisplatin by Genistein: The Role of NFκB and Akt/mTOR Signaling Pathways |
| Q36884668 | Serine 302 Phosphorylation of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling and Feedback Regulation by Hepatic S6 Kinase |
| Q91626057 | Serine Phosphorylation by mTORC1 Promotes IRS-1 Degradation through SCFβ-TRCP E3 Ubiquitin Ligase |
| Q37403970 | Serine kinases of insulin receptor substrate proteins |
| Q28513222 | Sestrin 3 protein enhances hepatic insulin sensitivity by direct activation of the mTORC2-Akt signaling |
| Q37302267 | Signal transduction cross talk mediated by Jun N-terminal kinase-interacting protein and insulin receptor substrate scaffold protein complexes |
| Q24522447 | Signaling by target of rapamycin proteins in cell growth control |
| Q37326084 | Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors |
| Q42908351 | Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis |
| Q84409733 | Sirolimus Therapy Predisposes to New-Onset Diabetes Mellitus After Renal Transplantation: A Long-Term Analysis of Various Treatment Regimens |
| Q37463518 | Skeletal muscle insulin resistance: the interplay of local lipid excess and mitochondrial dysfunction. |
| Q37030376 | Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. |
| Q40669345 | Specific killing of Rb mutant cancer cells by inactivating TSC2. |
| Q35983853 | Stress Responses Affecting Homeostasis of the Alveolar Capillary Unit |
| Q36623669 | Stress and mTORture signaling |
| Q26852093 | Stress in the kidney is the road to pERdition: is endoplasmic reticulum stress a pathogenic mediator of diabetic nephropathy? |
| Q36006981 | Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling |
| Q37321702 | Sulforaphane inhibits growth of phenotypically different breast cancer cells |
| Q35221417 | Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis |
| Q42436240 | Sustained overexpression of Redd1 leads to Akt activation involved in cell survival |
| Q39929967 | Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells |
| Q35714532 | TOR complex 2 (TORC2) in Dictyostelium suppresses phagocytic nutrient capture independently of TORC1-mediated nutrient sensing |
| Q35945269 | TOR coordinates bulk and targeted endocytosis in the Drosophila melanogaster fat body to regulate cell growth |
| Q34391710 | TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists |
| Q33787702 | TOR-dependent control of autophagy: biting the hand that feeds |
| Q37342465 | TOR-mediated autophagy regulates cell death in Drosophila neurodegenerative disease |
| Q45863420 | TOR-mediated regulation of metabolism in aging |
| Q43166689 | TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. |
| Q42216553 | TSC loss distorts DNA replication programme and sensitises cells to genotoxic stress |
| Q34565046 | TSC1 Controls Distribution of Actin Fibers through Its Effect on Function of Rho Family of Small GTPases and Regulates Cell Migration and Polarity |
| Q24297576 | TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation |
| Q34598209 | TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity |
| Q53279358 | TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade |
| Q34658958 | TSC2 deficiency increases PTEN via HIF1alpha |
| Q33873775 | Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures |
| Q35658860 | Targeted therapies for ER+/HER2- metastatic breast cancer |
| Q45743838 | Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. |
| Q38074121 | Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors |
| Q35138543 | Targeting Rb inactivation in cancers by synthetic lethality |
| Q37850227 | Targeting Translation Dependence in Cancer |
| Q37463917 | Targeting mTOR in renal cell carcinoma |
| Q38815881 | Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies |
| Q37265126 | Targeting the PI3-kinase/Akt/mTOR signaling pathway |
| Q33493174 | Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia |
| Q38102636 | Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding |
| Q37047669 | Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy |
| Q34632966 | Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. |
| Q36742629 | Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations |
| Q94564096 | The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor |
| Q24315972 | The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation |
| Q28829525 | The E3 ubiquitin ligase ZNRF2 is a substrate of mTORC1 and regulates its activation by amino acids |
| Q27013945 | The Insulin-Like Growth Factor System in Cancer |
| Q24620363 | The Lin28/let-7 axis regulates glucose metabolism |
| Q34828662 | The PTEN-PI3K pathway: of feedbacks and cross-talks |
| Q47119946 | The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling |
| Q37882389 | The Role of Phosphatidylinositol 3-Kinase Signaling Pathways in Pancreatic Cancer |
| Q52727884 | The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis. |
| Q41832120 | The TSC-mTOR pathway regulates macrophage polarization |
| Q36710799 | The TSC1-TSC2 complex is required for proper activation of mTOR complex 2 |
| Q24645204 | The TSC1-TSC2 complex: a molecular switchboard controlling cell growth |
| Q92884406 | The combination of loss of glyoxalase1 and obesity results in hyperglycemia |
| Q37300974 | The cullin7 E3 ubiquitin ligase: a novel player in growth control |
| Q38166578 | The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology |
| Q34318188 | The evolution of the TOR pathway and its role in cancer |
| Q27027797 | The expanding role of mTOR in cancer cell growth and proliferation |
| Q101140357 | The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer |
| Q40140184 | The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms |
| Q35124588 | The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer |
| Q24627306 | The mTOR Signalling Pathway in Human Cancer |
| Q39297991 | The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling. |
| Q33928657 | The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. |
| Q129334689 | The mTORC2 signaling network: targets and cross-talks |
| Q35894095 | The mitochondrial uncoupler DNP triggers brain cell mTOR signaling network reprogramming and CREB pathway up-regulation |
| Q27027262 | The pathogenic role of persistent milk signaling in mTORC1- and milk-microRNA-driven type 2 diabetes mellitus |
| Q34024558 | The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. |
| Q46147838 | The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation. |
| Q38655147 | The role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells |
| Q38695102 | The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. |
| Q37856373 | The tuberous sclerosis complex: balancing proliferation and survival |
| Q34167429 | Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going |
| Q38208069 | Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations |
| Q33556172 | Translational control during endoplasmic reticulum stress beyond phosphorylation of the translation initiation factor eIF2α. |
| Q33602544 | Tsc2 is a molecular checkpoint controlling osteoblast development and glucose homeostasis |
| Q53622635 | Tuberin activates the proapoptotic molecule BAD. |
| Q39408346 | Tuberous sclerosis complex: Recent advances in manifestations and therapy. |
| Q36313189 | Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease |
| Q34562010 | Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways |
| Q27014094 | Turning off AKT: PHLPP as a drug target |
| Q24670558 | Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis |
| Q34260622 | Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. |
| Q58447602 | Type 2 diabetes mellitus |
| Q35763142 | Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase. |
| Q24317018 | Upregulation of the mammalian target of rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic beta-cells leads to increased beta-cell mass and prevention of hyperglycemia |
| Q36623657 | Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? |
| Q38199196 | Use of mTOR inhibitors in the treatment of malignancies |
| Q26751078 | Using Drosophila to discover mechanisms underlying type 2 diabetes |
| Q38660086 | Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease. |
| Q28750492 | Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives |
| Q92330039 | ZDOG: zooming in on dominating genes with mutations in cancer pathways |
| Q30489319 | Zebrafish Tsc1 reveals functional interactions between the cilium and the TOR pathway |
| Q90402737 | mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand? |
| Q37156750 | mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss |
| Q38747508 | mTOR Signaling in Growth, Metabolism, and Disease. |
| Q29617779 | mTOR and cancer: insights into a complex relationship |
| Q92643974 | mTOR at the nexus of nutrition, growth, ageing and disease |
| Q42500373 | mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8. |
| Q29617214 | mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex |
| Q37097444 | mTOR couples cellular nutrient sensing to organismal metabolic homeostasis |
| Q38590634 | mTOR in health and in sickness |
| Q37863123 | mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy |
| Q29547767 | mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt |
| Q37597433 | mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma |
| Q39295436 | mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations |
| Q37710367 | mTOR signaling and drug development in cancer |
| Q33905253 | mTOR signaling in lymphangioleiomyomatosis |
| Q48293926 | mTOR signaling in stem and progenitor cells |
| Q37693034 | mTOR's role in ageing: protein synthesis or autophagy? |
| Q37926252 | mTOR: A pathogenic signaling pathway in developmental brain malformations |
| Q50578906 | mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. |
| Q38982579 | mTORC1 and mTORC2 in cancer and the tumor microenvironment |
| Q37597191 | mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development |
| Q41840986 | mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition |
| Q47748656 | mTORC1 loss impairs epidermal adhesion via TGF-β/Rho kinase activation |
| Q35984067 | mTORC1 signaling and regulation of pancreatic β-cell mass |
| Q39256910 | mTORC1 signaling in hepatic lipid metabolism |
| Q39765614 | mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling |
| Q34177457 | mTORC2 Is Required for Proliferation and Survival of TSC2-Null Cells |
| Q37151171 | miR-200a regulates Rheb-mediated amelioration of insulin resistance after duodenal-jejunal bypass |
| Q34299534 | microRNA-21 Governs TORC1 Activation in Renal Cancer Cell Proliferation and Invasion |
| Q34257789 | microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion |
| Q33292354 | p27Kip1 localization depends on the tumor suppressor protein tuberin |
| Q39395442 | p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation |
Search more.